NCT06021951View on ClinicalTrials.gov

Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women

PHASE4CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

August 4, 2023

Primary Completion Date

February 21, 2024

Study Completion Date

March 22, 2024

Conditions
Healthy Lactating Women
Interventions
DRUG

Bempedoic Acid 180 MG Oral Tablet

Bempedoic Acid 180 MG Oral Tablet \[Nexletol\]

DRUG

Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet

Bempedoic Acid/Ezetimibe 180 MG-10 MG Oral Tablet \[NEXLIZET\]

Trial Locations (1)

89113

PPD Development, Las Vegas Research Unit, Las Vegas

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY

NCT06021951 - Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women | Biotech Hunter | Biotech Hunter